Liraglutide with insulin improves poorly controlled Type 1 diabetes

June 25, 2012, The Endocrine Society

Obese adults with poorly controlled Type 1 diabetes can better control their blood sugar by adding liraglutide, a Type 2 diabetes drug, to their insulin therapy, a new study finds. The results, which will be presented at The Endocrine Society's 94th Annual Meeting in Houston, also found that these diabetic patients lost weight and lowered their blood pressure.

"These results are extremely relevant because in most patients with , the disease is not well controlled," said the study's main author, Paresh Dandona, MD, a professor at State University of New York (SUNY) at Buffalo and director, Diabetes-Endocrinology Center of Western New York, Williamsville. "At last we may be able to offer the Type 1 diabetic population a medication besides insulin."

Since the 1920s, insulin has been the only medical treatment of Type 1 diabetes. Last year Dandona and colleagues gained recognition for their initial study showing the benefits of treating well-controlled Type 1 diabetes using liraglutide plus insulin. Marketed as Victoza, liraglutide is a noninsulin injectable medicine that currently is approved only for adults with .

The "dramatic" effects in their first study led them to test whether patients with poorly controlled Type 1 diabetes would respond to liraglutide, Dandona said. The researchers therefore studied 27 obese adults, with an average age of 48, who had had Type 1 diabetes for 21 years on average. All had poor blood sugar control, as shown by a high hemoglobin A1c, a measure of over the past three months. Patients received liraglutide plus their usual .

After six months of liraglutide therapy, participants had significant improvements in their . Their fell from an average of 7.9 percent to 7.5 percent, according to Dandona. That value is closer to the less than 7 percent A1c that many diabetes organizations recommend for most people with diabetes. Similarly, the patients' average daily dose of insulin needed fell from 73 to less than 60 units, he reported.

The patients also lost about 10 pounds (4.6 kilograms) on average and lowered their body mass index from 33.4 to 31.7 kg/m2, which is in the low range of obesity.

In addition, their systolic blood pressure (the top number in a blood pressure reading) improved greatly. It dropped from an average of 130 to 120 millimeters of mercury (mm Hg), which is borderline normal. Statistical analysis showed that the blood pressure reduction was not related to weight loss, the investigators reported.

The improvements seen are important, Dandona said, because 40 to 50 percent of people with Type 1 diabetes have the metabolic syndrome. This cluster of risk factors, including high , large waistline, high , low HDL ("good") cholesterol and high triglycerides (fats in the blood), increases the chances of later developing Type 2 diabetes and heart disease.

Dandona called for large randomized clinical trials to further study the use of liraglutide in treating Type 1 diabetes, including finding the best dose. He reported no funding for this study.

Explore further: Study suggests drug significantly improves glycemic control in type one diabetics on insulin

Related Stories

Study suggests drug significantly improves glycemic control in type one diabetics on insulin

June 15, 2011
Results of a small, observational study conducted at the University at Buffalo suggest that liraglutide, an injectable medication used to treat type 2 diabetes, also helps type 1 diabetics on insulin achieve optimal control ...

Many people with type 1 diabetes missing treatment goals: study

June 10, 2012
(HealthDay) -- Many Americans with type 1 diabetes fail to meet their treatment targets, according to researchers who analyzed data from a newly created registry that includes more than 25,000 patients at 67 clinics nationwide.

Recommended for you

Genetic discovery may help better identify children at risk for type 1 diabetes

January 17, 2018
Six novel chromosomal regions identified by scientists leading a large, prospective study of children at risk for type 1 diabetes will enable the discovery of more genes that cause the disease and more targets for treating ...

Thirty-year study shows women who breastfeed for six months or more reduce their diabetes risk

January 16, 2018
In a long-term national study, breastfeeding for six months or longer cuts the risk of developing type 2 diabetes nearly in half for women throughout their childbearing years, according to new Kaiser Permanente research published ...

Women who have gestational diabetes in pregnancy are at higher risk of future health issues

January 16, 2018
Women who have gestational diabetes mellitus (GDM) during pregnancy have a higher than usual risk of developing type 2 diabetes, hypertension, and ischemic heart disease in the future, according to new research led by the ...

Diabetes gene found that causes low and high blood sugar levels in the same family

January 15, 2018
A study of families with rare blood sugar conditions has revealed a new gene thought to be critical in the regulation of insulin, the key hormone in diabetes.

Discovery could lead to new therapies for diabetics

January 12, 2018
New research by MDI Biological Laboratory scientist Sandra Rieger, Ph.D., and her team has demonstrated that an enzyme she had previously identified as playing a role in peripheral neuropathy induced by cancer chemotherapy ...

Enzyme shown to regulate inflammation and metabolism in fat tissue

January 11, 2018
The human body has two primary kinds of fat—white fat, which stores excess calories and is associated with obesity, and brown fat, which burns calories in order to produce heat and has garnered interest as a potential means ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.